Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

Could we personalise 1

line treatment?

Lin – JCO 2018 * Childress – Mol Cancer Res 2018

ALK v3 , higher mutations and

G1202R

even after 2

G ALK TKI

Lorlatinib 3

L, longer PFS in V3

. V1 (11

. 3.3)

After 2

G ALK TKI

After ALK TKI

IC50 crizotinib / alectinib similar for some fusions

Are the fusions correlated with M1 pattern?